Bill > SB0094

This bill aims to regulate interactions between drug manufacturers and pharmacies participating in the 340B drug pricing program, a federal program that allows certain healthcare organizations to purchase prescription drugs at discounted rates. The bill prohibits manufacturers, wholesalers, and wholesale distributor-brokers from denying, restricting, or discriminating against 340B entities or their contracted pharmacies when acquiring or delivering 340B drugs. Starting July 1, 2026, 340B entities will be required to submit annual reports to the department, including details about their program certification, community health needs assessments, compliance with federal regulations, and the program's impact on patients and communities. Simultaneously, manufacturers will need to report on prescription drugs that exceed $40 per treatment course and have experienced more than a 15% wholesale cost increase, providing detailed information such as drug pricing history, production costs, patent expiration, and drug dispensing forms. The department must publicly post these reports on its website. The bill defines key terms like "340B drug" and "340B entity" and allows such restrictions only when authorized by state or federal law. The bill is contingent upon the passage of companion legislation.

Government Affairs, Health and Social Services

https://legislature.mi.gov/Bills/Bill?ObjectName=2025-SB-0094